Company Overview of Targazyme, Inc.
Targazyme, Inc., a biotechnology company, develops and commercializes products in the fields of cell and immunotherapy. The company’s products include TZ101 that attaches the sugar fructose to therapeutic cells, such as stem cells or immune cells to increase the ability of those cells to attach to selectins, which are proteins that are up regulated under conditions of inflammation, ischemia, and tissue damage. Its TZ101 is used for various applications for patients with cancer, such as cord blood transplantation for hematological malignancies, regulatory T cells and mesenchymal stem cells for graft versus host diseases, and natural killer cells for multiple myeloma and leukemia; Ischemic dis...
3200 County Road 104
Floresville, TX 78114
Founded in 2005
Key Executives for Targazyme, Inc.
Co-Founder, Chairman and Chief Executive Officer
Head of Operations and Vice President of CMC
Senior Vice President of Regulatory Affairs & Quality Assurance
Compensation as of Fiscal Year 2016.
Targazyme, Inc. Key Developments
Targazyme, Inc. Receives FDA Clearance for Phase 2 Study of Pediatric Cancer Patients Undergoing Stem Cell Transplantation for Treatment of Hematologic Malignancies
Mar 6 17
Targazyme Inc. announced that the U.S. Food and Drug Administration (FDA) has granted IND Clearance to begin enrolling patients in a Phase 2 clinical study to evaluate the efficacy of TZ101-fucosylated hematopoietic stem cell transplants in pediatric cancer patients.
Targazyme, Inc. Receives FDA Clearance for A Phase II Haplo-Identical Transplant Study of Patients Undergoing Bone Marrow Transplantation
Oct 25 16
Targazyme Inc. announced that the U.S. Food and Drug Administration (FDA) has granted IND Clearance to begin enrolling patients in a Phase II clinical study to evaluate the safety and efficacy of TZ101-fucosylated bone marrow stem cells from haplo-identical donors in cancer patients. The transplantation of blood-forming stem cells from bone marrow is an accepted treatment to restore the body's ability to make blood and immune cells and is a treatment for various cancers like leukemia, lymphoma and some types of anemia. Recent medical advances have made possible the use of a haploidentical donor who is usually a 50% match to the recipient. Targazyme's product (TZ101) has the potential to improve the outcomes of this lifesaving treatment by improving the ability of TZ101 treated stem cells to home, adhere and engraft into the bone marrow, accelerating hematopoietic recovery, reducing both opportunistic infections and ICU/hospital stay for cancer patients undergoing the haplo-identical transplants.
Targazyme Enrolls First Patient in Phase 1/2 Study of TZ101 Fucosylated Regulatory T Cells
Jul 20 16
Targazyme, Inc. announced that it has enrolled the first patient in a Phase 1/2 TZ 101-treated regulatory T cell clinical study. This Phase 1/2 clinical study will evaluate the efficacy and safety of TZ101-treated regulatory T cells in the prevention and treatment of acute and chronic Graft-Versus-Host-Disease ("GVHD") in stem cell transplants. This clinical milestone will hopefully translate into the clinic the recent preclinical findings published in the journal Blood demonstrating the effectiveness of ex vivo treatment of regulatory T-cells with TZ101 in the prevention of GVHD.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries